Literature DB >> 16623620

Emergence of amphotericin B-resistant Cryptococcus laurentii meningoencephalitis shortly after treatment for Cryptococcus neoformans meningitis in a patient with AIDS.

Roberto Manfredi1, Ciro Fulgaro, Sergio Sabbatani, Giorgio Legnani, Gianni Fasulo.   

Abstract

A unique occurrence of two subsequent episodes of HIV-associated Cryptococcus neoformans followed by C. laurentii meningoencephalitis (successfully cured with fluconazole after demonstrated amphotericin B resistance) is presented and discussed. The available literature reported only two cases of HIV-associated C. laurentii infection to date, while a concurrent infection by C. neoformans and C. laurentii has been reported only once in a patient without HIV disease. The absence of prior descriptions of documented central nervous system infection by C. laurentii in non-HIV-infected patients is emphasized as well as the unpredictable in vitro and in vivo antifungal susceptibility of this non-neoformans Cryptococcus spp., and its apparent prevalence in hospitalized patients who received prior antifungal treatments. All epidemiologic, diagnostic, clinical, and therapeutic implications are discussed on the basis of the evolving characteristics of opportunism in the era of highly active antiretroviral therapy (HAART).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16623620     DOI: 10.1089/apc.2006.20.227

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  8 in total

1.  Antifungal susceptibility, enzymatic activity, PCR-fingerprinting and ITS sequencing of environmental Cryptococcus laurentii isolates from Uberaba, Minas Gerais, Brazil.

Authors:  Kennio Ferreira-Paim; Leonardo Andrade-Silva; Delio Jose Mora; Eliane Lages-Silva; André Luiz Pedrosa; Paulo Roberto da Silva; Anderson Assunção Andrade; Mario León Silva-Vergara
Journal:  Mycopathologia       Date:  2011-11-25       Impact factor: 2.574

2.  Cryptococcus laurentii biofilms: structure, development and antifungal drug resistance.

Authors:  K Ajesh; K Sreejith
Journal:  Mycopathologia       Date:  2012-09-01       Impact factor: 2.574

Review 3.  Synthesis of cell envelope glycoproteins of Cryptococcus laurentii.

Authors:  John Schutzbach; Helmut Ankel; Inka Brockhausen
Journal:  Carbohydr Res       Date:  2007-01-12       Impact factor: 2.104

4.  Phylogenetic analysis of phenotypically characterized Cryptococcus laurentii isolates reveals high frequency of cryptic species.

Authors:  Kennio Ferreira-Paim; Thatiana Bragine Ferreira; Leonardo Andrade-Silva; Delio Jose Mora; Deborah J Springer; Joseph Heitman; Fernanda Machado Fonseca; Dulcilena Matos; Márcia Souza Carvalho Melhem; Mario León Silva-Vergara
Journal:  PLoS One       Date:  2014-09-24       Impact factor: 3.240

5.  Pd@Ag Nanosheets in Combination with Amphotericin B Exert a Potent Anti-Cryptococcal Fungicidal Effect.

Authors:  Chao Zhang; Mei Chen; Guizhen Wang; Wei Fang; Chen Ye; Hanhua Hu; Zhenzong Fa; Jiu Yi; Wan-Qing Liao
Journal:  PLoS One       Date:  2016-06-07       Impact factor: 3.240

Review 6.  David and Goliath: chemical perturbation of eukaryotes by bacteria.

Authors:  Louis K Ho; Justin R Nodwell
Journal:  J Ind Microbiol Biotechnol       Date:  2015-10-03       Impact factor: 3.346

7.  Cryptococcus laurentii meningitis in a non-HIV patient.

Authors:  Miriams T Castro-Lainez; Rafael Deliz-Aguirre; Daphne Antunez; Marco Cruz-Codina; Lizbeth Cahuayme-Zuniga; Karla Vitale; Miguel Sierra-Hoffman; John K Midturi
Journal:  IDCases       Date:  2019-07-30

8.  Catheter-related infection due to Papiliotrema laurentii in an oncologic patient: Case report and systematic review.

Authors:  Marcos Rech Londero; Crisley Dossin Zanrosso; Leandro Luis Corso; Lessandra Michelin; Jonathan Soldera
Journal:  Braz J Infect Dis       Date:  2019-11-16       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.